These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1017 related articles for article (PubMed ID: 33982672)

  • 21. A majority of uninfected adults show preexisting antibody reactivity against SARS-CoV-2.
    Majdoubi A; Michalski C; O'Connell SE; Dada S; Narpala S; Gelinas J; Mehta D; Cheung C; Winkler DF; Basappa M; Liu AC; Görges M; Barakauskas VE; Irvine M; Mehalko J; Esposito D; Sekirov I; Jassem AN; Goldfarb DM; Pelech S; Douek DC; McDermott AB; Lavoie PM
    JCI Insight; 2021 Apr; 6(8):. PubMed ID: 33720905
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunoinformatic Analysis of SARS-CoV-2 Nucleocapsid Protein and Identification of COVID-19 Vaccine Targets.
    Oliveira SC; de Magalhães MTQ; Homan EJ
    Front Immunol; 2020; 11():587615. PubMed ID: 33193414
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evidence and implications of pre-existing humoral cross-reactive immunity to SARS-CoV-2.
    Mveang Nzoghe A; Essone PN; Leboueny M; Maloupazoa Siawaya AC; Bongho EC; Mvoundza Ndjindji O; Avome Houechenou RM; Agnandji ST; Djoba Siawaya JF
    Immun Inflamm Dis; 2021 Mar; 9(1):128-133. PubMed ID: 33320447
    [TBL] [Abstract][Full Text] [Related]  

  • 24. LY6E Restricts Entry of Human Coronaviruses, Including Currently Pandemic SARS-CoV-2.
    Zhao X; Zheng S; Chen D; Zheng M; Li X; Li G; Lin H; Chang J; Zeng H; Guo JT
    J Virol; 2020 Aug; 94(18):. PubMed ID: 32641482
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PD-1-Expressing SARS-CoV-2-Specific CD8
    Rha MS; Jeong HW; Ko JH; Choi SJ; Seo IH; Lee JS; Sa M; Kim AR; Joo EJ; Ahn JY; Kim JH; Song KH; Kim ES; Oh DH; Ahn MY; Choi HK; Jeon JH; Choi JP; Kim HB; Kim YK; Park SH; Choi WS; Choi JY; Peck KR; Shin EC
    Immunity; 2021 Jan; 54(1):44-52.e3. PubMed ID: 33338412
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exposure to SARS-CoV-2 generates T-cell memory in the absence of a detectable viral infection.
    Wang Z; Yang X; Zhong J; Zhou Y; Tang Z; Zhou H; He J; Mei X; Tang Y; Lin B; Chen Z; McCluskey J; Yang J; Corbett AJ; Ran P
    Nat Commun; 2021 Mar; 12(1):1724. PubMed ID: 33741972
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Age-Related Differences in Immunological Responses to SARS-CoV-2.
    Wong LSY; Loo EXL; Kang AYH; Lau HX; Tambyah PA; Tham EH
    J Allergy Clin Immunol Pract; 2020; 8(10):3251-3258. PubMed ID: 32861856
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Seroprevalence of SARS-CoV-2 in Guilan Province, Iran, April 2020.
    Shakiba M; Nazemipour M; Salari A; Mehrabian F; Nazari SSH; Rezvani SM; Ghasempour Z; Heidarzadeh A; Mansournia MA
    Emerg Infect Dis; 2021 Feb; 27(2):636-638. PubMed ID: 33349310
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Seroreactivity with COVID-19 antibody testing in CCP donors presenting without a SARS-CoV-2 diagnostic test.
    Goodhue Meyer EK; Xu M; Lasky B; Young PP
    Transfusion; 2021 Jan; 61(1):330-331. PubMed ID: 33037643
    [No Abstract]   [Full Text] [Related]  

  • 30. Coronaviruses in Balkan nephritis.
    Georgescu L; Diosi P; Buţiu I; Plavoşin L; Herzog G
    Am Heart J; 1980 Mar; 99(3):397-8. PubMed ID: 6243850
    [No Abstract]   [Full Text] [Related]  

  • 31. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study.
    Lopez Bernal J; Andrews N; Gower C; Robertson C; Stowe J; Tessier E; Simmons R; Cottrell S; Roberts R; O'Doherty M; Brown K; Cameron C; Stockton D; McMenamin J; Ramsay M
    BMJ; 2021 May; 373():n1088. PubMed ID: 33985964
    [TBL] [Abstract][Full Text] [Related]  

  • 32. mRNA vaccine-induced T cells respond identically to SARS-CoV-2 variants of concern but differ in longevity and homing properties depending on prior infection status.
    Neidleman J; Luo X; McGregor M; Xie G; Murray V; Greene WC; Lee SA; Roan NR
    bioRxiv; 2021 Jul; ():. PubMed ID: 34013277
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tocilizumab for the treatment of severe COVID-19.
    O'Leary K
    Nat Med; 2021 May; ():. PubMed ID: 33986543
    [No Abstract]   [Full Text] [Related]  

  • 34. Risk of clinical sequelae after the acute phase of SARS-CoV-2 infection: retrospective cohort study.
    Daugherty SE; Guo Y; Heath K; Dasmariñas MC; Jubilo KG; Samranvedhya J; Lipsitch M; Cohen K
    BMJ; 2021 May; 373():n1098. PubMed ID: 34011492
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long covid: coding is caring.
    Mayor N; Tsang R; Joy M; Hobbs FR; de Lusignan S
    BMJ; 2021 May; 373():n1262. PubMed ID: 34011495
    [No Abstract]   [Full Text] [Related]  

  • 36. Environmental perspective of COVID-19: Atmospheric and wastewater environment in relation to pandemic.
    Hu L; Deng WJ; Ying GG; Hong H
    Ecotoxicol Environ Saf; 2021 Aug; 219():112297. PubMed ID: 33991934
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sequelae, persistent symptomatology and outcomes after COVID-19 hospitalization: the ANCOHVID multicentre 6-month follow-up study.
    Romero-Duarte Á; Rivera-Izquierdo M; Guerrero-Fernández de Alba I; Pérez-Contreras M; Fernández-Martínez NF; Ruiz-Montero R; Serrano-Ortiz Á; González-Serna RO; Salcedo-Leal I; Jiménez-Mejías E; Cárdenas-Cruz A
    BMC Med; 2021 May; 19(1):129. PubMed ID: 34011359
    [TBL] [Abstract][Full Text] [Related]  

  • 38. COVID-19 Point-of-Care Diagnostics: Present and Future.
    Valera E; Jankelow A; Lim J; Kindratenko V; Ganguli A; White K; Kumar J; Bashir R
    ACS Nano; 2021 May; 15(5):7899-7906. PubMed ID: 33984237
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preexisting and Post-COVID-19 Immune Responses to SARS-CoV-2 in Patients with Cancer.
    Bilich T; Roerden M; Maringer Y; Nelde A; Heitmann JS; Dubbelaar ML; Peter A; Hörber S; Bauer J; Rieth J; Wacker M; Berner F; Flatz L; Held S; Brossart P; Märklin M; Wagner P; Erne E; Klein R; Rammensee HG; Salih HR; Walz JS
    Cancer Discov; 2021 Aug; 11(8):1982-1995. PubMed ID: 34011563
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Experience with the use of siltuximab in patients with SARS-CoV-2 infection.
    Meira F; Albiach L; Carbonell C; Martín-Oterino JA; Martín-Ordiales M; Linares L; Macaya I; Agüero D; Ambrosioni J; Bodro M; Cardozo C; Chumbita M; De la Mora M; García-Pouton N; Garcia-Vidal C; González-Cordón A; Hernández-Meneses M; Inciarte A; Laguno M; Leal L; Morata L; Puerta-Alcalde P; Rico V; Letona L; Cózar-Llistó A; Dueñas G; Solá M; Torres B; Rojas J; Moreno A; Moreno-García E; Torres M; Martínez JA; Soriano A; García F
    Rev Esp Quimioter; 2021 Aug; 34(4):337-341. PubMed ID: 33982984
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 51.